A biopharmaceutical company has received GBP 7.6 million, after launching a trial that looks into the effectiveness of a drug used in the fight against diabetes.
Tolerx received the milestone payment from GlaxoSmithKline, after announcing the start of a phase III clinical trial to evaluate otelixizumab in autoimmune new onset type 1 diabetes.
The trial, a durable response therapy evaluation for early or new onset type 1 diabetes (Defend), is a randomised, placebo controlled phase III trial conducted across North America and Europe.
It will evaluate whether a single course of otelixizumab, administered not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes, will reduce the amount of administered insulin required to control blood glucose levels by inhibiting the destruction of beta cells.
Dr Douglas Ringler, president and CCEO of Tolerx, said: “We are excited to have dosed the first patient in Defend and look forward to continued patient enrolment in this phase III clinical trial. The initiation of Defend represents the culmination of a methodical, dose-ranging development plan, including the successful outcome from an end-of-phase II meeting at FDA.”
Copyright PA Business 2008